Eli Lilly’s $1 trillion valuation cements its status as Wall Street’s ultimate weight-loss play
Eli Lilly (LLY) is back above $1 trillion, closing at its first record high since November, as Wall…
Nektar, continuing comeback, says eczema drug’s effects hold up in follow-up study
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free…
Identification of potential drug targets for achalasia from genetic insights: a Mendelian randomization study | Journal of Cardiothoracic Surgery
Acquisition of data and identification of instrumental variables To identify common single nucleotide polymorphisms (SNPs, population minor allele…